Results 171 to 180 of about 3,037 (201)
Some of the next articles are maybe not open access.

Epidural lornoxicam administration – innocent

Journal of Clinical Neuroscience, 2007
We aimed to determine the analgesic efficacy and clinical or histopathological neurotoxicity of epidural single-dose lornoxicam. Caudal epidural catheters were inserted into 28 rabbits, divided into four groups, on day 1. Pain latency and degree of motor and sensory loss for each animal for different concentrations of lornoxicam were determined on day ...
Canduz, Basak   +7 more
openaire   +3 more sources

Clinical Pharmacokinetics of Lornoxicam

Clinical Pharmacokinetics, 1998
Lornoxican (chlorotenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours). Lornoxicam is eliminated following biotransformation to 5'-hydroxy-lornoxicam, which does not undergo enterohepatic recirculation.
N M, Skjodt, N M, Davies
openaire   +2 more sources

Formulation and evaluation of proniosomes containing lornoxicam

Drug Delivery and Translational Research, 2016
Proniosomes are the new generation provesicular drug delivery system of non-ionic surfactant, lecithin and cholesterol which upon reconstitution get converted into niosomes. The objective of current study was to develop stable and sustain transdermal delivery system for lornoxicam.
Madan, Jyotsana R.   +2 more
openaire   +2 more sources

Preoperative peritonsillar lornoxicam infiltration is not superior to intravenous lornoxicam for pain relief following tonsillectomy in adults

European Journal of Anaesthesiology, 2010
Nonsteroidal anti-inflammatory drugs have peripheral analgesic effects. We compared the efficacy of peritonsillar infiltration versus intravenous (i.v.) lornoxicam on pain relief after tonsillectomy in adults.Sixty adult patients scheduled for tonsillectomy were randomly assigned into three groups in a double-blind placebo-controlled study.
Salah A, Ismail, Hany A, Mowafi
openaire   +2 more sources

Lornoxicam in clinical practice.

Postgraduate medical journal, 1991
Three studies reported here have confirmed that lornoxicam is effective in osteoarthritis and the ideal dose appears to be 12 mg daily. Overall, lornoxicam appears to be a useful drug in the treatment of both osteo- and rheumatoid arthritis, from the data presently available.
H, Berry, S, Ollier
openaire   +1 more source

Lornoxicam Salts: Crystal Structures, Conformations, and Solubility

Crystal Growth & Design, 2014
Lornoxicam (LXM), a nonsteroidal anti-inflammatory drug (NSAID), is an amphiprotic molecule that exists as a zwitterion in the solid state. The formation of two strong intramolecular N+–H···O and N–H···O– hydrogen bonds in a stable six-member ring geometry, S(6), renders this otherwise flexible molecule in a rigid conformation (conformer A).
Kuthuru Suresh, Ashwini Nangia
openaire   +1 more source

Pharmacokinetics of lornoxicam in man.

Postgraduate medical journal, 1991
Clinical phase I pharmacokinetic studies with lornoxicam were performed with the 4 mg dose of lornoxicam. Lornoxicam was administered as an aqueous solution both orally and intravenously to young, healthy, male volunteers. The total excretion of lornoxicam via urine and faeces after oral administration was determined by administering 14C-labelled ...
G, Hitzenberger   +3 more
openaire   +1 more source

Clinical pharmacokinetic studies with lornoxicam.

Postgraduate medical journal, 1991
Pharmacokinetic data from several studies in young and elderly human subjects are reviewed. Lornoxicam appears to be extensively metabolized and no unchanged drug has been found in the urine. It has a relatively short elimination half-life (about 4 hours), and no significant differences in pharmacokinetic data have been found between young and elderly ...
P, Turner, A, Johnston
openaire   +1 more source

Lornoxicam

Reactions Weekly, 2007
openaire   +2 more sources

Home - About - Disclaimer - Privacy